An interventional study of lobectomy and segmentectomy or wedge resection in Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology. Active, not recruiting at 386 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Alliance for Clinical Trials in Oncology · Interventional
RATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve recovery. It is not yet known whether wedge resection or segmentectomy are more effective than lobectomy in treating stage IA non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying different types of surgery to compare how well they work in treating patients with stage IA non-small cell lung cancer.
OUTLINE: This is a multicenter, randomized study. Patients are stratified according to tumor size (\< 1 cm vs 1-1.5 cm vs > 1.5-2.0 cm) (based on the maximum dimension determined from the preoperative CT scan), histology (squamous cell carcinoma vs adenocarcinoma vs other), and smoking status (never smoked [smoked \< 100 cigarettes over lifetime] vs former smoker [smoked > 100 cigarettes AND quit ≥ 1 year ago] vs current smoker [quit \< 1 year ago or currently smokes]). Patients are randomized to 1 of 2 treatment arms. For more information, please see the Arms section.
Primary Objective:
To determine whether DFS after sublobar resection (segmentectomy or wedge) is non-inferior to that after lobectomy in patients with small peripheral (≤ 2 cm) NSCLC.
Secondary Objectives:
After completion of study treatment, patients are followed up every 6 months for 2 years and then annually for 5 years.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,558 are open to participants now.
Browse Lung Neoplasms studies →Alliance for Clinical Trials in Oncology is the lead sponsor of 499 studies on the registry; 27 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Pre-registration Eligibility Criteria:
Intra-operative Randomization Eligibility Criteria:
Patients undergo a standard operation for lung cancer called a lobectomy.
Procedure: lobectomy
Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
Procedure: segmentectomy or wedge resection
disease-free survival
Time frame: Up to 7 years
overall survival
Time frame: Up to 7 years
rate of loco-regional and systemic recurrence
Time frame: Up to 7 years
pulmonary function as measured by expiratory flow rate 6 months postoperatively
Time frame: at 6 months
Showing the first 100 of 386 sites across 3 countries.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alliance for Clinical Trials in Oncology